The T-cell engager (TCE) field has seen unprecedented growth, with eight approvals in the past two years—most recently tarlatamab—reinforcing its potential as a dominant force in immuno-oncology. Expanding applications in autoimmune diseases and a surge in business development, including Merck and Co.’s acquisition of Harpoon Therapeutics and GSK’s $550M agreement with Chimagen, highlight the industry’s commitment to advancing this modality.

The 7th T-Cell Engager Therapeutics Summit remains the only event exclusively focused on translating TCEs and immune cell engagers from discovery to the clinic and regulatory approval. This year’s program will showcase innovations to improve efficacy and safety in solid tumors while exploring new opportunities in autoimmune indications.

Time: 8:30 AM – 4:20 PM

Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Joonhee Park, Senior Scientist, Amgen, Saso Cemerski, Executive Director, Immune Engagers, AstraZeneca, Flavio Lima Bianchi, Lead Research Analyst, Beacon, Simon Plyte, Chief Scientific Officer, Biomunex, Alexander Martinko, Director, Antibody Engineering and Design, Cartography Bio, Anthony Stein, Associate Director, Gehr Family Center for Leukemia Research City of Hope, Lauren Harshman, Senior Vice President, Clinical Development, Clasp Therapeutics, Kris Sachsenmeier, Vice President, Translational Sciences, Compass Therapeutics,  and more